Literature DB >> 10895052

Antagonism of nitrous oxide antinociception in mice by intrathecally administered antisera to endogenous opioid peptides.

F J Cahill1, E A Ellenberger, J L Mueller, L F Tseng, R M Quock.   

Abstract

Previously it was demonstrated that nitrous oxide antinociception in the mouse abdominal constriction test is mediated by kappa-opioid receptors. Since nitrous oxide is thought to cause the neuronal release of endogenous opioid peptide to stimulate opioid receptors, this study was designed to identify the opioid peptides involved, especially in the spinal cord, by determining whether nitrous oxide antinociception can be differentially inhibited by intrathecally (i. t.) administered antisera to different opioid peptides. Male NIH Swiss mice were pretreated i.t. with rabbit antisera to opioid peptides then exposed 24 h later to one of three different concentrations of nitrous oxide in oxygen. Dose-response curves constructed from the data indicated that the antinociceptive effect of nitrous oxide was significantly antagonized by antisera to various dynorphins (DYNs) and methionine-enkephalin (ME), but not by antiserum to beta-endorphin (beta-EP). The AD(50) values for nitrous oxide antinociception were significantly elevated by antisera to DYNs and ME but not beta-EP. These findings of this study support the hypothesis that nitrous oxide antinociception in the mouse abdominal constriction test involves the neuronal release of DYN and ME in the spinal cord. Copyright 2000 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10895052     DOI: 10.1007/BF02253248

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  9 in total

1.  Involvement of spinal cord opioid mechanisms in the acute antinociceptive effect of hyperbaric oxygen in mice.

Authors:  Jacqueline H Heeman; Yangmiao Zhang; Donald Y Shirachi; Raymond M Quock
Journal:  Brain Res       Date:  2013-10-07       Impact factor: 3.252

2.  Involvement of a NO-cyclic GMP-PKG signaling pathway in nitrous oxide-induced antinociception in mice.

Authors:  Yao Zhang; Lindsay P Quock; Eunhee Chung; Yusuke Ohgami; Raymond M Quock
Journal:  Eur J Pharmacol       Date:  2011-01-14       Impact factor: 4.432

3.  Nitrous oxide-induced NO-dependent neuronal release of β-endorphin from the rat arcuate nucleus and periaqueductal gray.

Authors:  Yusuke Ohgami; Eunhee Chung; Raymond M Quock
Journal:  Brain Res       Date:  2010-11-06       Impact factor: 3.252

Review 4.  Advances in understanding the actions of nitrous oxide.

Authors:  Dimitris E Emmanouil; Raymond M Quock
Journal:  Anesth Prog       Date:  2007

Review 5.  Neurobiology of nitrous oxide-induced antinociceptive effects.

Authors:  Masahiko Fujinaga; Mervyn Maze
Journal:  Mol Neurobiol       Date:  2002-04       Impact factor: 5.590

6.  Antagonism of the antinociceptive effect of nitrous oxide by inhibition of enzyme activity or expression of neuronal nitric oxide synthase in the mouse brain and spinal cord.

Authors:  Jessica Lack Cope; Eunhee Chung; Yusuke Ohgami; Raymond M Quock
Journal:  Eur J Pharmacol       Date:  2009-10-08       Impact factor: 4.432

7.  A prolonged nitric oxide-dependent, opioid-mediated antinociceptive effect of hyperbaric oxygen in mice.

Authors:  Lisa M Zelinski; Yusuke Ohgami; Eunhee Chung; Donald Y Shirachi; Raymond M Quock
Journal:  J Pain       Date:  2008-10-31       Impact factor: 5.820

8.  Nitrous oxide-antinociception is mediated by opioid receptors and nitric oxide in the periaqueductal gray region of the midbrain.

Authors:  Dimitris E Emmanouil; Andrea S Dickens; Rick W Heckert; Yusuke Ohgami; Eunhee Chung; Shujie Han; Raymond M Quock
Journal:  Eur Neuropsychopharmacol       Date:  2007-08-01       Impact factor: 4.600

9.  Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome.

Authors:  Tsukasa Nozu; Saori Miyagishi; Rintaro Nozu; Kaoru Takakusaki; Toshikatsu Okumura
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.